OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
BEVERLY, Mass. and TORONTO, May 01, 2018 -- Hamilton Thorne Ltd. (TSX-V:HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today announced that David Wolf, President and CEO of Hamilton Thorne Ltd., will present at the 2018 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Hotel Toronto on Thursday May 3, 2018 at 11:00 a.m. Eastern Time.
The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly
traded and private companies through presentations and private meetings.
About Hamilton Thorne Ltd. (www.hamiltonthorne.com)
Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.
Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.
For more information, please contact:
David Wolf, President & CEO
Hamilton Thorne Ltd.
978-921-2050
[email protected]
Michael Bruns, CFO
Hamilton Thorne Ltd.
978-921-2050
[email protected]
Glen Akselrod
Bristol Investor Relations
905-326-1888
[email protected]
